Meet Emerald Clinical’s Experts at ASCO 2026
Chicago, May 30 – June 1, 2026
Booth 23149
Book a Meeting with Us
Connect with Luke Gill, Vice President Global Head of Oncology; Thomas Barfield Senior Director, Project Delivery; and Sachin Kulkarni, Therapeutic Strategy Head, Oncology at the 2025 ASCO Annual Meeting.
Partner with Emerald Clinical Trials to advance oncology development. Aligning with ASCO’s 2025 theme of improving global outcomes, we leverage our deep APAC heritage and global reach—backed by 700+ studies and 106,000 patients. Our collaborative study start-up solutions combine scientific leadership with operational expertise to deliver patient-centric, efficient, and regulatory-compliant results worldwide
Do you need support to navigate the China regulatory process?
For sponsors running Oncology PoC Phase I/II programs, regulatory complexity can introduce risk, delay recruitment, and slow critical readouts.
China’s National Medical Products Administration (NMPA) has a 30 day fast track review pathway for eligible innovative drugs—down from the 60 day timeline—designed to accelerate trial start up and patient access.
At Emerald Clinical, we provide the expertise, local presence, and regulatory guidance to help you fully leverage this pathway.
✅ We have successfully supported NMPA approvals in under 30 days.
✅ Our China based teams are ready to help you de-risk recruitment and accelerate your trials.
Book a Meeting with Us
Emerald Clinical Advantage
We’ve done it. We can help you do it better. Our team brings over 25+ years of cross-functional industry experience to every stage of your study, specializing in:
- Strategic Planning: Early-stage strategies designed for faster regulatory approval and commercial success.
- Regulatory Navigation: Expertly managing the complexities of rapidly shifting global regulatory environments.
- Site Identification: Robust feasibility studies that lead to superior site selection.
- Scientific and Medical Affair Engagement: Leveraging expert advice to drive faster recruitment and higher patient retention.
- Early Phase Excellence: Dedicated teams with specialized knowledge in Australian R&D tax benefits.
- Global Reach: Access to qualified sites and patient populations in 70 countries.
Meet our Team
Learn more about our Oncology Capabilities
Dan Gallagher MBA
Dan Gallagher is a senior commercial leader on Emerald Clinical Executive Team with over 15…
